Cardiovascular toxicity associated with small molecule tyrosine kinase inhibitors currently in clinical use

Bibliography

• Orphanos GS, Ioannidis GN, Ardavanis AG, Cardiotoxicity induced by tyrosine kinase inhibitors. Acta Oncol 2009;48:964-70
   PubMed Web of Science ®Google Scholar
• Kerkela R, Grazette L, Yacobi R, Cardiotoxicity of the cancer therapeutic agent imatinib mesylate. Nat Med 2006;12:908-16
   PubMed Web of Science ®Google Scholar
• Krause DS, Van Etten RA. Tyrosine kinases as targets for cancer therapy. N Engl J Med 2005;353:172-87
   PubMed Web of Science ®Google Scholar
• Force T, Krause DS, Van Etten RA, Molecular mechanisms of cardiotoxicity of tyrosine kinase inhibition. Nat Rev Cancer 2007;7:332-44
   PubMed Web of Science ®Google Scholar
• Ron D, Walter P. Signal integration in the endoplasmic reticulum unfolded protein response. Nat Rev Mol Cell Biol 2007;8:519-29
   PubMed Web of Science ®Google Scholar
• Steinberg SF. Distinctive activation mechanisms and functions for protein kinase C delta. Biochem J 2004;384:449-59
   PubMed Web of Science ®Google Scholar
• Bantscheff M, Eberhard D, Abraham Y, Quantitative chemical proteomics reveals mechanisms of action of clinical ABL kinase inhibitors. Nat Biotechnol 2007;25:1035-44
   PubMed Web of Science ®Google Scholar
• Guilhot F, Druker B, Larson RA, High rates of durable response are achieved with imatinib after treatment with interferon a plus cytarabine: results from the international randomized study of interferon and STI571 (IRIS) trial. Haematologica 2009;94:1669-75
   PubMed Web of Science ®Google Scholar
• Wei G, Rafiyath S, Liu D. First-line treatment for chronic myeloid leukemia: dasatinib, nilotinib or imatinib. J Hematol Oncol 2010;3:47
   PubMed Web of Science ®Google Scholar
• Park YH, Park HJ, Kim BS, BNP as a marker of the heart failure in the treatment of imatinib mesylate. Cancer Lett 2006;243:16-22
   PubMed Web of Science ®Google Scholar
• Trent JC, Patel SS, Zhang J, Rare incidence of congestive heart failure in gastrointestinal stromal tumor and other sarcoma patients receiving imatinib mesylate. Cancer 2010;116:184-92
   PubMed Web of Science ®Google Scholar
• Turrisi G, Montagnani F, Grotti S, Congestive heart failure in imatinib mesylate treatment. Int J Cardiol 2010;145:148-50
   PubMed Web of Science ®Google Scholar
• Telli ML, Witteles RM, Fisher GA, Cardiotoxicity associated with the cancer therapeutic agent sunitinib malate. Ann Oncol 2008;19:1613-18
   PubMed Web of Science ®Google Scholar
• Hasinoff BB. The cardiotoxicity and myocyte damage caused by small molecule anticancer tyrosine kinase inhibitors is correlated with lack of target specificity. Toxicol Appl Pharmacol 2010;244:190-5
   PubMed Web of Science ®Google Scholar
• Schmidinger M, Zielinski CC, Vogl UM, Cardiac toxicity of sunitinib and sorafenib in patients with metastatic renal cell carcinoma. J Clin Oncol 2008;26:5204-12
   PubMed Web of Science ®Google Scholar
• Kerkela R, Woulfe KC, Durand JB, Sunitinib-induced cardiotoxicity is mediated by off-target inhibition of AMP-activated protein kinase. Clin Transl Sci 2009;2:15-25
   PubMed Web of Science ®Google Scholar
• Schmidinger M, Vogl UM, Schukro C, Cardiac involvement in patients with sorafenib or sunitinib treatment for metastatic renal cell carcinoma. ASCO Annual Meeting Proceedings Part 1. J Clin Oncol 2007;25(18S):5110
   Google Scholar
• Cohen JD, Babiarz JE, Abrams RM, Use of human stem cell derived cardiomyocytes to examine sunitinib mediated cardiotoxicity and electrophysiological alterations. Toxicol Appl Pharmacol 2011;257:74-83
   PubMed Web of Science ®Google Scholar
• Witteles RM, Harshman LC, Telli M, Prospective cardiotoxicity screening during tyrosine kinase inhibitor therapy for renal cell carcinoma: an institutional experience. J Clin Oncol 2009;27(Suppl):abstract e16003
   Google Scholar
• Demetri GD, van Oosterom AT, Garrett CR, Efficacy and safety of sunitinib in patients with advanced gastrointestinal stromal tumour after failure of imatinib: a randomised controlled trial. Lancet 2006;368:1329-38
   PubMed Web of Science ®Google Scholar
• Motzer RJ, Hutson TE, Tomczak P, Overall survival and updated results for sunitinib compared with interferon alfa in patients with metastatic renal cell carcinoma. J Clin Oncol 2009;27:3584-90
   PubMed Web of Science ®Google Scholar
• Sutent prescribing information, 2006. Available from: http://www.sutent.com
   Google Scholar
• Giles FJ, O'Dwyer M, Swords R, Class effects of tyrosine kinase inhibitors in the treatment of chronic myeloid leukemia. Leukemia 2009;23:1698-707
   PubMed Web of Science ®Google Scholar
• Bello CL, Mulay M, Huang X, Electrocardiographic characterization of the QTc interval in patients with advanced solid tumors: pharmacokinetic- pharmacodynamic evaluation of sunitinib. Clin Cancer Res 2009;15:7045-52
   PubMed Web of Science ®Google Scholar
• Wu CF, Chuang WP, Li AH, Cardiac magnetic resonance imaging in sunitinib malate-related cardiomyopathy: no late gadolinium enhancement. J Chin Med Assoc 2009;72:323-7
   PubMed Web of Science ®Google Scholar
• Flaherty KT, Puzanov I, Kim KB, Inhibition of mutated, activated BRAF in metastatic melanoma. N Engl J Med 2010;363:809-19
   PubMed Web of Science ®Google Scholar
• Hasinoff BB, Patel D. The lack of target specificity of small molecule anticancer kinase inhibitors is correlated with their ability to damage myocytes in vitro. Toxicol Appl Pharmacol 2010;249:132-9
   PubMed Web of Science ®Google Scholar
• Roberts PJ, Der CJ. Targeting the Raf-MEK-ERK mitogen-activated protein kinase cascade for the treatment of cancer. Oncogene 2007;26:3291-310
   PubMed Web of Science ®Google Scholar
• Yamaguchi O, Watanabe T, Nishida K, Cardiac-specific disruption of the c-RAF-1 gene induces cardiac dysfunction and apoptosis. J Clin Invest 2004;114:937-43
   PubMed Web of Science ®Google Scholar
• Hasinoff BB, Patel D. Mechanisms of myocyte cytotoxicity induced by the multikinase inhibitor sorafenib. Cardiovasc Toxicol 2010;10:1-8
   PubMed Web of Science ®Google Scholar
• French KJ, Coatney RW, Renniger JP, Differences in effects on myocardium and mitochondria by angiogenic inhibitors suggest separate mechanisms of cardiotoxicity. Toxicol Pathol 2010;38:691-702
   PubMed Web of Science ®Google Scholar
• Carmeliet P. VEGF as a key mediator of angiogenesis in cancer. Oncology 2005;69(Suppl 3):4-10
   PubMed Web of Science ®Google Scholar
• Bayer Pharmaceuticals. Nexavar (sorafenib) Prescribing Information. Bayer Pharmaceuticals; 2007. Available from: http://www.pfizer.com/files/products/uspi_sutent.pdf
   Google Scholar
• Bayer Pharmaceuticals. Nexavar (sorafenib) NDA Pharmacology Review. Bayer Pharmaceuticals; 2005. Available from: http://www.accessdata.fda.gov/drugsatfda_docs/nda/2005/021923_s000_Nexavar_PharmR.pdf
   Google Scholar
• FDA. 2009.FDA sorafenib product label information 2009. Available from: http://www.fda.gov/AboutFDA/CentersOffices/CDER/ucm129234.htm
   Google Scholar
• Porto I, Leo A, Miele L, A case of variant angina in a patient under chronic treatment with sorafenib. Nat Rev Clin Oncol 2010;7:476-80
   PubMed Web of Science ®Google Scholar
• Naib T, Steingart RM, Chen CL. Sorafenib-associated multivessel coronary artery vasospasm. Herz 2011;36:348-51
   PubMedGoogle Scholar
• Kim SO, Han SY, Baek YH, Splenic infarction associated with sorafenib use in a hepatocellular carcinoma patient. World J Gastroenterol 2011;17:267-70
   PubMed Web of Science ®Google Scholar
• Schutz FA, Bellmunt YJ, Rosenberg TK, Risk of arterial thromboembolic events with sunitib and sorafenib: a systemic review and meta-analysis of clinical trials [abstract 346]. ASCO Genitourinary Cancers Symposium; 2010
   Google Scholar
• Mardiak J, Mego M, Urbanova D, High resolution electrocardiography in detection of preclinical cardiotoxicity of sunitib and sorafenib in renal cell carcinoma (RCC) patients. J Clin Oncol 2008;26(Suppl):abstract 16097
   Google Scholar
• Jezdic S, Popov I. EGF receptor as a therapeutic target in oncology. Arch Oncol 2005;13(Suppl 1):53-5
   Google Scholar
• Imai K, Takaoka A. Comparing antibody and small-molecule therapies for cancer. Nat Rev Cancer 2006;6:714-22
   PubMed Web of Science ®Google Scholar
• Ling YH, Lin R, Perez-Soler R. Erlotinib induces mitochondrial-mediated apoptosis in human H3255 non-small-cell lung cancer cells with epidermal growth factor receptor mutation through mitochondrial oxidative phosphorylation-dependent activation of BAX and BAK. Mol Pharmacol 2008;74:793-806
   PubMed Web of Science ®Google Scholar
• Spector NL, Yarden Y, Smith B, Activation of AMP-activated protein kinase by human EGF receptor 2/EGF receptor tyrosine kinase inhibitor protects cardiac cells. PNAS 2007;104:10607-12
   PubMed Web of Science ®Google Scholar
• Pore N, Jiang Z, Gupta A, EGFR tyrosine kinase inhibitors decrease VEGF expression by both hypoxia-inducible factor (HIF)-1–independent and HIF-1–dependent mechanisms. Cancer Res 2006;66:3197-204
   PubMed Web of Science ®Google Scholar
• Tarceva prescribing information, 2004. Available from: http://www.tarceva.com
   Google Scholar
• Noma T, Lemaire A, Naga Prasad SV, Beta-arrestin-mediated beta1-adrenergic receptor transactivation of the EGFR confers cardioprotection. J Clin Invest 2007;117:2445-58
   PubMed Web of Science ®Google Scholar
• Salmi R, Gaudenzi P, Di Todaro F, Massive thrombosis of brachiocephalic veins and superior vena cava syndrome in a patient with non-small cell lung cancer treated with the epidermal growth factor receptor inhibitor erlotinib. Clin Drug Investig 2007;27:499-503
   PubMed Web of Science ®Google Scholar
• Bukowski RM, Yasothan U, Kirkpatrick P. Pazopanib. Nat Rev Drug Discov 2010;9:17-18
   PubMed Web of Science ®Google Scholar
• Rini BI. VEGF-Targeted Therapy in Metastatic Renal Cell Carcinoma. Oncologist 2005;10:191-7
   PubMed Web of Science ®Google Scholar
• Lang JM, Harrison MR. Pazopanib for the treatment of patients with advanced renal cell carcinoma. Clin Med Insight Oncol 2010;4:95-105
   PubMedGoogle Scholar
• Yla-Herttuala S, Rissanen TT, Vajanto I, Vascular endothelial growth factors. J Am Coll Cardiol 2007;49:1015-26
   PubMed Web of Science ®Google Scholar
• Votrient (pazopanib) prescribing information, 2010. Available from: http://www.VOTRIENT.com
   Google Scholar
• Roden DM. Drug-induced prolongation of the QT interval. N Engl J Med 2004;350:1013-22
   PubMed Web of Science ®Google Scholar
• Strevel EL, Ing DJ, Siu LL. Molecularly targeted oncology therapeutics and prolongation of the QT interval. J Clin Oncol 2007;25:3362-71
   PubMed Web of Science ®Google Scholar
• Will Y, Dykens JA, Nadanaciva S, Effect of the multitargeted tyrosine kinase inhibitors imatinib, dasatinib, sunitinib, and sorafenib on mitochondrial function in isolated rat heart mitochondria and H9c2 cells. Toxicol Sci 2008;106:153-61
   PubMed Web of Science ®Google Scholar
• Kantarjian H, Cortes J, Kim D, Phase III study of dasatinib 140 mg once daily versus 70 mg twice daily in patients with chronic myeloid leukemia in accelerated phase resistant or intolerant to imatinib: 15-month median follow-up. Blood 2009;113:6322-39
   PubMed Web of Science ®Google Scholar
• Kantarjian H, Shah NP, Hochhaus A, Dasatinib versus imatinib in newly diagnosed chronic-phase chronic myeloid leukemia. N Engl J Med 2010;362:2260-70
   PubMed Web of Science ®Google Scholar
• Quintas-Cardama A, Kantarjian H, O'Brien S, Pleural effusion in patients with chronic myelogenous leukemia treated with dasatinib after imatinib failure. J Clin Oncol 2007;25:3908-14
   PubMed Web of Science ®Google Scholar
• Sprycel prescribing information, 2006. Available from: http://www.sprycel.com
   Google Scholar
• Francis J, Ahluwalia MS, Wetzler M, Reversible cardiotoxicity with tyrosine kinase inhibitors. Clin Adv Hematol Oncol 2010;8:128-32
   PubMedGoogle Scholar
• Gaballa S, Al-Kali A, Kantarjian H, Pulmonary hypertension (PH) in patients with CML treated with tyrosine kinase inhibitors (TKIs). J Clin Oncol 2010;28(15s Suppl):abstract 6597
   Google Scholar
• Weisberg E, Manley P, Mestan J, AMN107 (nilotinib): a novel and selective inhibitor of BCR-ABL. Br J Cancer 2006;94:1765-9
   PubMed Web of Science ®Google Scholar
• Blay JY, von Mehren M. Nilotinib: a novel, selective tyrosine kinase inhibitor. Semin Oncol 2011;38(Suppl 1):S3-9
   PubMedGoogle Scholar
• Rix U, Hantschel O, Durnberger G, Chemical proteomic profiles of the BCR-ABL inhibitors imatinib, nilotinib, and dasatinib reveal novel kinase and nonkinase targets. Blood 2007;110:4055-63
   PubMed Web of Science ®Google Scholar
• Wang CH, Anderson N, Li SH, Stem cell factor deficiency is vasculoprotective: unraveling a new therapeutic potential of imatinib mesylate. Circ Res 2006;99:617-25
   PubMed Web of Science ®Google Scholar
• Novartis: Tasigna (nilotinib) US prescribing information, revised June 2010
   Google Scholar
• Kantarjian H, Giles F, Wunderle L, Nilotinib in imatinib-resistant CML and Philadelphia chromosome-positive ALL. N Engl J Med 2006;354:2542-51
   PubMed Web of Science ®Google Scholar
• Brauchli YB, Wais T, Gratwohl A, Fatal myocardial infarction during nilotinib treatment in a 60-year-old male patient. Acta Oncol (Madr) 2010;49:523-5
   PubMed Web of Science ®Google Scholar
• Aichberger KJ, Herndlhofer S, Schernthaner GH, Progressive peripheral arterial occlusive disease and other vascular events during nilotinib therapy in CML. Am J Hematol 2011;86:533-9
   PubMed Web of Science ®Google Scholar
• Moy B, Kirkpatrick P, Kar S, Lapatinib. Nat Rev Drug Discov 2007;6:431-2
   PubMed Web of Science ®Google Scholar
• Negro A, Brar BK, Lee KF. Essential Roles of Her2/erbB2 in cardiac development and function. Recent Prog Horm Res 2004;59:1-12
   PubMedGoogle Scholar
• Crone SA, Zhao YY, Fan L, ErbB2 is essential in the prevention of dilated cardiomyopathy. Nat Med 2002;8:459-65
   PubMed Web of Science ®Google Scholar
• Ozcelik C, Erdmann B, Pilz B, Conditional mutation of the ErbB2 (HER2) receptor in cardiomyocytes leads to dilated cardiomyopathy. Proc Natl Acad Sci 2002;99:8880-5
   PubMed Web of Science ®Google Scholar
• Grazette LP, Boecker W, Matsui T, Inhibition of ErbB2 causes mitochondrial dysfunction in cardiomyocytes: implications for herceptin-induced cardiomyopathy. J Am Coll Cardiol 2004;44:2231-8
   PubMed Web of Science ®Google Scholar
• Bacus SS, Spector NL. Targeted therapy to ERBB receptor in breast cancer affect metabolic pathways: implications to cardiac toxicity and cancer response. ASCO Breast Cancer Symposium; General Poster Session B. J Clin Oncol 2007;25 (18s), Abstract 14000
   Google Scholar
• Perez EA, Koehler M, Byrne J, Cardiac safety of lapatinib: pooled analysis of 3689 patients enrolled in clinical trials. Mayo Clin Proc 2008;83:679-86
   PubMed Web of Science ®Google Scholar
• Chatsiproios D. Safety profile and clinical recommendations for the use of lapatinib. Breast Care 2010;5(Suppl 1):16-21
   PubMedGoogle Scholar
• Tykerb prescribing information, 2007. Available from: http://www.tykerb.com
   Google Scholar
• Dancey J, Sausville EA. Issues and progress with protein kinase inhibitors for cancer treatment. Nat Rev Drug Discov 2003;1:296-313
   Google Scholar
• Zhang L, Gjoerup O, Roberts TM. The serine/threonine kinase cyclin G-associated kinase regulates epidermal growth factor receptor signaling. Proc Natl Acad Sci USA 2004;101:10296-301
   PubMed Web of Science ®Google Scholar
• Brehmer D, Greff Z, Godl K, Cellular targets of gefitinib. Cancer Res 2005;65:379-82
   PubMed Web of Science ®Google Scholar
• Matsui T, Tao J, del Monte F, Akt activation preserves cardiac function and prevents injury after transient cardiac ischemia in vivo. Circulation 2001;104:330-5
   PubMed Web of Science ®Google Scholar
• Lynch DR, Kickler TS, Rade JJ. Recurrent myocardial infarction associated with gefitinib therapy. J Thromb Thrombolysis 2011;32:120-4
   PubMed Web of Science ®Google Scholar
• Iressa prescribing information, 2005. Available from: http://www.iressa.com
   Google Scholar
• Xalkori prescribing information, 2011. Available from: http://www.XALKORI.com
   Google Scholar
• Shaw AT, Yeap BY, Solomon BJ, Effect of crizotinib on overall survival in patients with advanced non-small-cell lung cancer harbouring ALK gene rearrangement: a retrospective analysis. Lancet Oncol 2011;12:1004-12
   PubMed Web of Science ®Google Scholar
• Chapman PB, Hauschild A, Robert C, Improved survival with vemurafenib in melanoma with BRAF V600E mutation. N Engl J Med 2011;364:2507-16
   PubMed Web of Science ®Google Scholar
• ZELBORAF prescribing information, 2011. Available from: http://www.ZELBORAF.com
   Google Scholar